|
See related Dysport powd for inj information |
|
|
|
Manufacturer |
BEAUFOUR IPSEN |
|
Distributor |
Hong Kong: LF Asia |
|
Contents |
Clostridium botulinum type A toxin-haemagglutinin complex |
|
Indications |
Listed in Dosage.
Click to view Dysport detailed prescribing infomation |
|
Dosage |
Adult spasticity of arm post stroke 1,000 u distributed among 5 muscles repeated approx 16 wk, but not more frequently than every 8 wk. Paed cerebral palsy spasticity 20 u/kg as a divided dose between both calf muscle or 10 u/kg if only 1 calf is affected. Max: Up to 1,000 u/patient. May be repeated approx 16 wk, but not more frequently than every 8 wk. Spasmodic torticollis Adult & elderly Initially 500 u/patient given in a divided dose & administered to 2 or 3 most active neck muscles. Repeat approx 8-12 wk or as required. Blepharospasm & hemifacial spasm Initially 120 u/eye repeated every 8 wk or as required for bilateral blepharospasm. Confine inj to affected eye in unilateral blepharospasm & hemifacial spasm.
Click to view Dysport detailed prescribing infomation |
|
Overdosage |
View Dysport overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Pregnancy.
Click to view Dysport detailed prescribing infomation |
|
Special Precautions |
Subclinical or clinical evidence of marked defective neuromuscular transmission.
Click to view Dysport detailed prescribing infomation |
|
Adverse Drug Reactions |
Adult spasticity of arm post-stroke: Muscle weakness, infection, flu-syndrome, dry mouth, myasthenia, pain, constipation, diarrhoea, pharyngitis & somnolence. Paed cerebral palsy spasticity: Leg pain, pharyngitis, accidental injury, bronchitis, fever. Spasmodic torticollis: Burning sensation, dysphagia. Blepharospasm & hemifacial spasm: Exacerbation of preexisting eyelid abnormalities, ptosis, diplopia, spread of the paralytic effect to mid-facial muscles.
View ADR Monitoring Form |
|
Drug Interactions |
[Click for Dysport detailed prescribing infomation]
View more drug interactions with Dysport |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Dysport detailed prescribing infomation |
|
Storage |
View Dysport storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Dysport description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Dysport mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
